The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
Open accessAbstract
CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients but are dysfunctional. Here we developed a tamoxifen-inducible liver cancer mouse model with a defined oncogenic driver antigen (SV40 large T-antigen) to follow the activation and differentiation of naive tumor-specific CD8(+) T (TST) cells after tumor initiation. Early during the pre-malignant phase of tumorigenesis, TST cells became dysfunctional, exhibiting phenotypic, functional, and transcriptional features similar to dysfunctional T cells isolated from late-stage human tumors. Thus, T cell dysfunction seen in advanced human cancers may already be established early during tumorigenesis. Although the TST cell dysfunctional state was initially therapeutically reversible, it ultimately evolved into a fixed state. Persistent antigen exposure rather than factors associated with the tumor microenvironment drove dysfunction. Moreover, the TST cell differentiation and dysfunction program exhibited features distinct from T cell exhaustion in chronic infections. Strategies to overcome this antigen-driven, cell-intrinsic dysfunction may be required to improve cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Profiling adoptively transferred SV40 large T cell antigen (Tag+)–specific CD8+ T cells indicated that Tag+ T cells followed classic signs of exhaustion upon entry into the tumor-bearing livers (fig. S2D) (19).”
From Bile acid synthesis impedes tumor-specific T cell responses during liver cancer (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, terminal Tex (Ttex) cells accumulate over time and respond poorly to ICB therapies8,11–13.”
From Proteotoxic stress response drives T cell exhaustion and immune evasion (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, the T cell immune response to HCC antigens is reportedly dysfunctional and unreactive to HCC55.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“…studies have demonstrated that blocking inhibitory receptors (checkpoint blockade) can mediate functional rescue of unresponsive T cells in chronic infection or tumors (Barber et al., 2006; Brahmer et al., 2012; Perez-Gracia et al., 2014; (A) Tamoxifen (Tam)-inducible ASTxCre-ERT2 tumor model.”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Cited by
Sorted by citations
Items 301–400 of 726
Yin, Q., Yu, W., Grzeskowiak, C. L., Li, J., Huang, H., Guo, J., Chen, L., Wang, F., Zhao, F., von Boehmer, L., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016168118 · Cited by 32
Exploiting the obesity-associated immune microenvironment for cancer therapeutics
Desharnais, L., Walsh, L. A., & Quail, D. F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107923 · Cited by 31
Wang, Z., Liu, Y., Zhang, J., Zhao, R., Zhou, X., & Wang, H. (2021) · Journal of Oncology · doi:10.1155/2021/9972454 · Cited by 31
Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice
Nath, P. R., Pal-Nath, D., Kaur, S., Gangaplara, A., Meyer, T. J., Cam, M. C., & Roberts, D. D. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2111909 · Cited by 31
Ao, Y.-Q., Gao, J., Jin, C., Wang, S., Zhang, L., Deng, J., Chen, Z.-W., Wang, H., Jiang, J.-H., & Ding, J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007766 · Cited by 31
Blise, K. E., Sivagnanam, S., Betts, C. B., Betre, K., Kirchberger, N. C., Tate, B. J., Furth, E. E., Costa, A. D., Nowak, J. A., Wolpin, B. M., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0873 · Cited by 31
Huang, K., Jayant, K., Lee, P., Yang, P.-C., Hsiao, C., Habib, N., & Sodergren, M. H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030385 · Cited by 30
Novel Mouse Models for Cancer Immunology
Connolly, K. A., Fitzgerald, B., Damo, M., & Joshi, N. S. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-105523 · Cited by 31
Barboy, O., Bercovich, A., Li, H., Eyal-Lubling, Y., Yalin, A., Itai, Y. S., Abadie, K., Zada, M., David, E., Shlomi-Loubaton, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00734-z · Cited by 32
Elia, A. R., Caputo, S., & Bellone, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01786 · Cited by 30
Abdel-Hakeem, M. S. (2019) · Viruses · doi:10.3390/v11020106 · Cited by 29
Prognostic Values of CD38+CD101+PD1+CD8+ T Cells in Pancreatic Cancer
Zhang, M., Yang, J., Zhou, J., Gao, W., Zhang, Y., Lin, Y., Wang, H., Ruan, Z., & Ni, B. (2019) · Immunological Investigations · doi:10.1080/08820139.2019.1566356 · Cited by 29
Tissue environment, not ontogeny, defines murine intestinal intraepithelial T lymphocytes
Brenes, A. J., Vandereyken, M., James, O. J., Watt, H. J., Hukelmann, J. L., Spinelli, L., Dikovskaya, D., Lamond, A. I., & Swamy, M. (2021) · eLife · doi:10.7554/elife.70055 · Cited by 28
Asiry, S., Kim, G., Filippou, P. S., Sanchez, L. R., Entenberg, D. R., Marks, D. K., Oktay, M. H., & Karagiannis, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654877 · Cited by 29
Viral and cellular oncogenes promote immune evasion
Roetman, J. J., Apostolova, M. K. I., & Philip, M. (2022) · Oncogene · doi:10.1038/s41388-021-02145-1 · Cited by 32
Self-citationBeider, K., Itzhaki, O., Schachter, J., Grushchenko-Polaq, A. H., Voevoda-Dimenshtein, V., Rosenberg, E., Ostrovsky, O., Devillers, O., Frommer, R. S., Zeltzer, L., et al. (2022) · Cells · doi:10.3390/cells11071140 · Cited by 30
Determinants of anti-PD1 response and resistance in clear cell renal cell carcinomaPreprint
Au, L., Hatipoglu, E., de Massy, M. R., Litchfield, K., Rowan, A., Thompson, R. H., Schnidrig, D., Byrne, F., Beattie, G., Horswell, S. D., et al. (2021) · medRxiv · doi:10.1101/2021.03.19.21253661 · Cited by 29
Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy
Pasquarelli-do-Nascimento, G., Machado, S. A., de Carvalho, J. M. A., & Magalhães, K. G. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac015 · Cited by 29
Leukapheresis for CAR-T cell production and therapy
Pessach, I., & Nagler, A. (2023) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2023.103828 · Cited by 32
Byl, W. V. D., Nüssing, S., Peters, T. J., Ahn, A., Li, H., Ledergor, G., David, E., Koh, A. S., Wagle, M. V., Deguit, C. D. T., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.04.026 · Cited by 32
Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells
Nelson, C. E., Mills, L. J., McCurtain, J. L., Thompson, E. A., Seelig, D. M., Bhela, S., Quarnstrom, C. F., Fife, B. T., & Vezys, V. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810326116 · Cited by 27
Teoh, J. J., & Brown, L. F. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.03.013 · Cited by 29
Witt, M., Oliveira‐Ferrer, L., Koch‐Nolte, F., Menzel, S., Hell, L., Sturmheit, T., Seubert, E., Weimer, P., Ding, Y., Qi, M., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2346359 · Cited by 29
Yu, X., Zhang, L., Chaudhry, A., Rapaport, A. S., & Ouyang, W. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.6mr0320-234r · Cited by 25
Golonka, R. M., & Vijay–Kumar, M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.10.004 · Cited by 28
Takeda, Y., Yoshida, S., Takashima, K., Ishii‐Mugikura, N., Shime, H., Seya, T., & Matsumoto, M. (2018) · Cancer Science · doi:10.1111/cas.13649 · Cited by 27
Shields, N. J., Peyroux, E. M., Ferguson, A. L., Steain, M. C., Neumann, S., & Young, S. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152035 · Cited by 31
Kim, S.-H., Cho, E., Kim, Y. I., Han, C., Choi, B. K., & Kwon, B. S. (2021) · Nature Communications · doi:10.1038/s41467-021-25559-7 · Cited by 28
Marciscano, A. E. E., Walker, J. M., McGee, H. M., Kim, M. M., Kunos, C. A., Monjazeb, A. M., Shiao, S. L., Tran, P. T., & Ahmed, M. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0317-y · Cited by 27
Ohta, K., Sakoda, Y., Adachi, K., Shinozaki, T., Nakajima, M., Yasuda, H., Nagano, H., & Tamada, K. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0226 · Cited by 30
CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy
Feng, D., Pu, D., Ren, J., Liu, M., Zhang, Z., Liu, Z., & Li, J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189193 · Cited by 26
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade
Alden, S. L., Charmsaz, S., Li, H. L., Tsai, H., Danilova, L., Munjal, K., Brancati, M., Warner, A., Howe, K., Griffin, E., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009734 · Cited by 29
Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance
Zadka, Ł., Grybowski, D. J., & Dzięgiel, P. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00519-3 · Cited by 26
Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers
Zhou, G., Boor, P. P. C., Bruno, M. J., Sprengers, D., & Kwekkeboom, J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01453-3 · Cited by 25
O'Reilly, M. A., Malhi, A., Cheok, K. P. L., Ings, S. J., Balsa, C., Keane, H., Jalowiec, K. A., Neill, L., Peggs, K. S., & Roddie, C. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.10.012 · Cited by 25
Intratumoral antigen signaling traps CD8 + T cells to confine exhaustion to the tumor site
Takahashi, M., So, T. Y., Chamberlain-Evans, V., Hughes, R., Yam‐Puc, J. C., Kania, K., Ruhle, M., Mann, T., Schuijs, M. J., Coupland, P. G., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.ade2094 · Cited by 23
Zhou, X., Zhao, S., He, Y., Geng, S., Shi, Y., & Wang, B. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1250 · Cited by 25
Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance
Martinov, T., & Fife, B. T. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14106 · Cited by 28
Li, M., Jiang, A., Han, H., Chen, M., Wang, B., Cheng, Y., Zhang, H., Wang, X., Dai, W., Yang, W., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c03352 · Cited by 24
The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells
Liao, X., Li, W., Zhou, H., Rajendran, B. K., Li, A., Ren, J., Luan, Y., Calderwood, D., Turk, B. E., Tang, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44885-0 · Cited by 27
Deng, Y., Xia, L. P., Zhang, J., Deng, S., Wang, M., Wei, S., Li, K., Lai, H., Yang, Y., Bai, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101489 · Cited by 24
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
Sun, Y., Yinwang, E., Wang, S., Wang, Z., Wang, F., Xue, Y., Zhang, W., Zhao, S., Mou, H., Chen, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02104-w · Cited by 29
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 24
Retnakumar, S. V., Chauvin, C., & Bayry, J. (2023) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2023.108399 · Cited by 21
Banerjee, S., Ansari, A. A., Upadhyay, S. P., Mettman, D. J., Hibdon, J. R., Quadir, M., Ghosh, P., Kambhampati, A., & Banerjee, S. K. (2024) · Cells · doi:10.3390/cells13050395 · Cited by 24
Stock, S., Hoffmann, J., Schubert, M., Wang, L., Wang, S., Gong, W., Neuber, B., Gern, U., Schmitt, A., Müller‐Tidow, C., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.237 · Cited by 24
Kerdidani, D., Magkouta, S., Chouvardas, P., Karavana, V. N., Glynos, K., Roumelioti, F., Zakynthinos, S. G., Wauters, E., Janssens, W., Lambrechts, D., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700700 · Cited by 24
Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
Weng, C., Assouvie, A., Dong, L., Beltra, J., Budhu, S., Mangarin, L. M. B., Marouf, Y., Morgado-Palacin, L., Liu, C., Monette, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02321-5 · Cited by 24
Shim, K. G., Zaidi, S., Thompson, J., Kottke, T., Evgin, L., Rajani, K. R., Schuelke, M. R., Driscoll, C. B., Huff, A. L., Pulido, J. S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.023 · Cited by 23
Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy
Smith, P. L., Piadel, K., & Dalgleish, A. G. (2021) · Vaccines · doi:10.3390/vaccines9121392 · Cited by 24
DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity
Kureshi, R., Bello, E., Kureshi, C. T. S., Walsh, M. J., Lippert, V., Hoffman, M. T., Dougan, M. L., Longmire, T. A., Wichroski, M. J., & Dougan, S. K. (2023) · Science Advances · doi:10.1126/sciadv.adk1853 · Cited by 20
CD38–RyR2 axis–mediated signaling impedes CD8 + T cell response to anti-PD1 therapy in cancer
Kar, A., Ghosh, P., Gautam, A., Chowdhury, S., Basak, D., Sarkar, I., Bhoumik, A., Barman, S., Chakraborty, P., Mukhopadhyay, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315989121 · Cited by 23
The pros and cons of dying tumour cells in adaptive immune responses
Wang, X., Lu, X., & Sun, B. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.87 · Cited by 22
Luo, H., Wang, W., Mai, J., Yin, R., Cai, X., & Li, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1267918 · Cited by 22
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness
Lin, C., Levy, P. L., Alflen, A., Apriamashvili, G., Ligtenberg, M. A., Vredevoogd, D. W., Bleijerveld, O. B., Alkan, F., Malka, Y., Hoekman, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.016 · Cited by 21
Overcoming Resistance Mechanisms to Melanoma Immunotherapy
Zheng, D. X., Bozym, D. J., Tarantino, G., Sullivan, R. J., Liu, D., & Jenkins, R. W. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00907-7 · Cited by 25
Reticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 23
The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
Zhylko, A., Winiarska, M., & Graczyk‐Jarzynka, A. (2020) · Cancers · doi:10.3390/cancers12082030 · Cited by 21
Sugiyarto, G., Lau, D., Hill, S. L., Arcia, D., Boulanger, D. S. M., Parkes, E. E., James, E., & Elliott, T. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007114 · Cited by 22
Ambler, R., Edmunds, G. L., Tan, S. L., Cirillo, S., Pernes, J. I., Ruan, X., Huete‐Carrasco, J., Wong, C. C. W., Lu, J., Ward, J., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aau4518 · Cited by 23
Prokhnevska, N., Emerson, D. A., Kissick, H. T., & Redmond, W. L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_7 · Cited by 21
Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy
Bouziana, S. D., & Bouzianas, D. G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103096 · Cited by 20
Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells
Zhang, F., Ding, X., Huang, H., Jiang, H., Jiang, J., & Zheng, X. W. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0105 · Cited by 25
Zhou, J., Wang, W., Liang, Z., Ni, B., He, W., & Wang, D. (2020) · Oncology Letters · doi:10.3892/ol.2020.11580 · Cited by 20
Chimeric antigen receptor T-cell therapy for multiple myeloma
Wang, Z., Chen, C., Wang, L., Jia, Y., & Qin, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050522 · Cited by 21
Sarén, T., Ramachandran, M., Gammelgård, G., Lövgren, T., Mirabello, C., Björklund, Å. K., Wikstrom, K. I., Hashemi, J., Freyhult, E., Ahlström, H. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0178 · Cited by 19
Nguyen, K. B., Roerden, M., Copeland, C., Backlund, C. M., Klop-Packel, N. G., Remba, T. K., Kim, B., Singh, N. K., Birnbaum, M. E., Irvine, D. J., et al. (2023) · eLife · doi:10.7554/elife.85263 · Cited by 20
T cell landscape in the microenvironment of human solid tumors
Maggi, E., Munari, E., Landolina, N., Mariotti, F. R., Azzarone, B. G., & Moretta, L. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106942 · Cited by 22
Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure
Viganó, S., Bobisse, S., Coukos, G., Perreau, M., & Harari, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01350 · Cited by 21
Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer
Zhang, C., Sheng, Q., Zhang, X., Xu, K., Jin, X., Zhou, W., Zhang, M., Lv, D., Yang, C., Li, Y., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106484 · Cited by 21
Immunological exhaustion: How to make a disparate concept operational?
Kaminski, H., Lemoine, M., & Pradeu, T. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009892 · Cited by 20
New Developments in T Cell Immunometabolism and Implications for Cancer Immunotherapy
Oberholtzer, N. P., Quinn, K. M., Chakraborty, P., & Mehrotra, S. (2022) · Cells · doi:10.3390/cells11040708 · Cited by 19
Fueling HCC Dynamics: Interplay Between Tumor Microenvironment and Tumor Initiating Cells
Huang, H., Tsui, Y., & Ng, I. O. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.01.007 · Cited by 19
T Cell Exhaustion: An Epigenetically Imprinted Phenotypic and Functional Makeover
Alfei, F., & Zehn, D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.07.006 · Cited by 19
Cheng, Y., Shao, Z., Chen, L., Zheng, Q., Zhang, Q., Ding, W., Zhang, M., Yu, Q., & Gao, D. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.11.004 · Cited by 20
New cytometry tools for immune monitoring during cancer immunotherapy
Sanjabi, S., & Lear, S. P. (2021) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21984 · Cited by 20
Weber, E. W., Lynn, R. C., Parker, K. R., Anbunathan, H., Lattin, J., Sotillo, E., Good, Z., Malipatlolla, M., Xu, P., Vandris, P., et al. (2020) · doi:10.1101/2020.01.26.920496 · Cited by 18
“Chronic antigen stimulation induces T cell exhaustion, a differentiation state associated with a heritable epigenetic imprint that is distinct from that found in effector and memory T cells (Pauken et al., 2016; Philip et al., 2017; Schietinger et al., 2012; Schietinger et al., 2016; Sen et al., 2016; Wherry et al., 2…”
BackgroundHeidari‐Foroozan, M., Rezalotfi, A., & Rezaei, N. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2401352 · Cited by 19
CD4+ T cell dysfunction in cancer
Venkatesh, H., & Fong, L. H. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241417 · Cited by 19
Wang, X., Wang, J., Wang, Q., Ding, G., Huang, Y., & Feng, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189536 · Cited by 19
Katano, I., Hanazawa, A., Otsuka, I., Yamaguchi, T., Mochizuki, M., Kawai, K., Ito, R., Goto, M., Kagawa, T., & Takahashi, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-00641-8 · Cited by 19
Application of ATAC-seq in tumor-specific T cell exhaustion
Chen, C., Liu, J., Chen, Y., Lin, A., Mou, W., Zhu, L., Yang, T., Cheng, Q., Zhang, J., & Luo, P. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00495-w · Cited by 19
Yang, Y., Li, X., Liu, F., Ma, M., Yang, Y., Ruan, C., Lü, Y., Li, X., Wang, X., Shi, Y., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174600 · Cited by 19
Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps
Rodrigo, B. N., Ortiz-Miranda, Y., Corría-Osorio, J., Coukos, G., & Harari, A. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.002 · Cited by 22
Mulholland, M., Chalou, A., Andersson, S. H. A., Depuydt, M. A. C., Yu, Y., Lin, S., Tallbäck, K., Ericsson, A., Jakobsson, G., de Mol, J., et al. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00713-2 · Cited by 19
Jiang, H., Limsuwannarot, S. P., Kulhanek, K. R., Pal, A., Labiad, O., Rysavy, L. W., Wong, A., Su, L., Cavender, S. M., Soro, J., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.024 · Cited by 18
Nie, W., Fan, W., Jiang, A., Wu, G., Liu, H., Huang, L.-L., & Xie, H. (2021) · Science China Chemistry · doi:10.1007/s11426-021-1085-8 · Cited by 17
Kongkaew, T., Thaiwong, R., Tudsamran, S., Sae‐jung, T., Sengprasert, P., Vasuratna, A., Suppipat, K., & Reantragoon, R. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113229 · Cited by 16
Liu, D., Qi, X., Wei, X., Zhao, L., Wang, X., Li, S., Wang, Z., Shi, L., Xu, J., Mei, H., et al. (2022) · Theranostics · doi:10.7150/thno.75037 · Cited by 17
TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses
Harris, R., Mammadli, M., Hiner, S., Suo, L., Yang, Q., Sen, J. M., & Karimi, M. A. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03323-0 · Cited by 17
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
Mulgaonkar, A., Udayakumar, D., Yang, Y., Harris, S. F., Öz, O. K., Geethakumari, P. R., & Sun, X. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1199146 · Cited by 18
The host protecting the tumor from the host — targeting PD‑L1 expressed by host cells
Munn, D. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99047 · Cited by 17
Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
Dong, Y., Gao, J., Pei, M., Wang, X., Zhang, C., Du, Y., & Jiang, Y. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s242463 · Cited by 17
Mechanisms of Immune Modulation by Radiation
Spina, C. S., & Drake, C. G. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.02.001 · Cited by 17
Olguín-Contreras, L. F., Mendler, A. N., Popowicz, G. M., Hu, B., & Noeßner, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.750478 · Cited by 16
Moustaki, A., Crawford, J. C., Alli, S., Fan, Y., Boi, S. K., Zamora, A. E., McDonald, N., Wu, G., Nakitandwe, J., Newman, S., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abf6136 · Cited by 17
PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype
Wagner, A. K., Kadri, N., Tibbitt, C. A., van de Ven, K., Singh, S. B., Oliinyk, D., LeGresley, E., Campbell, N., Trittel, S., Riese, P., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105137 · Cited by 21
Attias, M., & Piccirillo, C. A. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16313 · Cited by 17
T-cell localization, activation and clonal expansion in human pancreatic ductal adenocarcinoma
Stromnes, I., Hulbert, A., Pierce, R., Greenberg, P., & Hingorani, S. (2018) · immuneACCESS · doi:10.21417/b7305d · Cited by 16
Self-citationThe Role of Programmed Death-1 in Type 1 Diabetes
Tucker, C., Dwyer, A. J., Fife, B. T., & Martinov, T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01384-6 · Cited by 16
Metadata
- Authors
- Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., Schell, T. D., Garbi, N., & Greenberg, P. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Aduro BioTech (United States) (US)
- German Cancer Research Center (DE)
- Pennsylvania State University (US)
- University of Bonn (DE)
- Corresponding author
- Schietinger, Andrea
- Greenberg, Philip D.
- ORCID
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 45
- Issue
- 2
- Pages
- 389-401
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC5119632
- OpenAlex
- W2514996992
- Cited by
- 720
- References
- 60
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 93 · 2023: 84 · 2022: 78 · 2021: 103 · 2020: 99 · 2019: 61 · 2018: 50 · 2017: 25 · 2016: 5
- FWCI
- 25.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R00CA172371, K99CA172371, K08CA158069, R01CA033084, P30CA008748, P30CA015704)
- National Institute of Allergy and Infectious Diseases (R21AI107776)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-specific T cells, CD8+ T cell dysfunction, carcinogenesis, SV40 large T antigen, liver cancer, T cell differentiation, T cell exhaustion, cancer immunotherapy
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, Cell Differentiation, Cells, Cultured, Disease Models, Animal, Humans, Liver Neoplasms, Lymphocyte Activation, Mice, Inbred C57BL, Mice, Transgenic, Tamoxifen, Immunotherapy, Adoptive, Cellular Senescence, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
